Found: economy annually, 10 equivalent to 6% of the UK economy, and more than the automotive, aerospace, life

Found: Health and life sciences, including rural health, telemedicine , and health technology; d.

Found: solutions (including hydrogen and carbon capture, utilisation, and storage), chemicals, health and life

Found: speech to the Nuffield Trust, I talked about the NHS having an M&S moment, and, to me, tech, AI and life

Question to the Department of Health and Social Care:

To ask His Majesty's Government what incentives they are offering to medical partnerships to assist type two diabetes sufferers through research into both stem-cell and non-stem-cell treatments for diabetes type one sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what incentives they are offering to commercial operators to form medical partnerships to advance stem-cell and non-stem-cell treatments for diabetes type one sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to promote international cooperation and joint research to find solutions for both type one and type two diabetes sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what partnerships and expedients they are encouraging to progress diabetes type one stem cell and non-stem-cell research.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of (a) funding and (b) support available for research into non-invasive cancer monitoring technologies.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23 and the NIHR spends more on cancer than any other disease group.

In terms of adequacy of funding, the NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

Regarding technologies, the NIHR’s Invention for Innovation (i4i) Programme is a translational research funding scheme aimed at supporting medical devices, such as non-invasive cancer monitoring technologies, and includes in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need. Further information is available at the following link:

https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm

Additionally, in September 2023, the Office for Life Sciences Cancer Mission launched the £12 million NIHR i4i Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call, aiming to support the clinical validation and evaluation of breakthrough technologies that can increase the proportion of cancers that are detected earlier in the disease course and target health inequalities in cancer diagnosis.

The NIHR continues to welcome and encourage funding applications for research into any aspect of human health, including cancer monitoring technologies, and it is worth noting that all applications that were fundable in open competition, have been funded.

Question to the Department for Transport:

To ask the Secretary of State for Transport, if he will make an assessment of the potential impact of East West Rail on science and technology activities in locations on that route.

Answered by Huw Merriman - Minister of State (Department for Transport)

The Government has a strong desire to maintain and enhance our position as a global science and technology superpower and we recognise the importance of the Oxford-Cambridge region as a globally renowned hub of science, research and innovation, with businesses and universities that are leading the way in life sciences, space and green technologies. At the East West Rail Route Update Announcement in May 2023, it was reconfirmed that East West Rail would approach to Cambridge from the south, serving the new Cambridge South station, and promoting greater economic growth given the proximity of the Biomedical Campus to Cambridge South station.

Found: this project will support will include collaborations with clinical scientists, other academics in life

Found: UK Government funding will help transform the Bught Park stadium and site Johh Lamont 2023-11-24 UHI Life

Found: Attendees by sector Actuals Target # +/- difference Financial & Professional Services 46 20 26 Life

Found: Life Sciences Vision Missions

Found: bespoke learning and professional development opportunities across the UK’s world-leading Deep Tech and Life

Found: learning and professional development opportunities across the UK’s world- leading Deep Tech and Life

Found: Thomas’ , Director of Innovation Cancer & Surgery at Guy’s and St Thomas’, Clinical Advisor at Advent Life

Found: strive for a future with accessible, effective mental health therapies, advancing the UK as a leader in life

Found: focus on one of the Chancellor’s five priority sectors – digital and technology; green industries; life

Found: technologies and innovations, and support businesses in important sectors such as manufacturing, health and life

Found: The discussion focused on ‘Future Frontiers: Applications at the Intersection of AI, Life Sciences, and

Found: Attitudes to Animal Research survey, previously conducted by Ipsos M ORI and funded by the Office for Life

Found: trials application The MHRA’s agile regulatory framework for clinical trials supports innovation in the life

Found: BIOPLUS LIFE SCIENCES PRIVATE LIMITED, PHARMED GARDENS, WHITEFIELD ROAD, BANGALORE, IN-560048, INDIA

Found: Given the UK’s desire to maintain its leading position in biotechnology and other life sciences and

Found: 230640406 Dept of Health MHRA 30/08/2023 Application Services and Maintenance Digital and Technology LORENZ Life

Found: Life Sciences Vision Missions

Found: Genomics & HDR -UK) Secretariat: Government Office for Science Officials Observers: Office for Life